Major Study Reveals Surprising Culprit Behind 1 in 8 Cancer Cases Globally

A sweeping new global analysis has placed infection-related cancer squarely in the spotlight, with researchers at the International Agency for Research on Cancer (IARC) determining that roughly one in eight new cancer cases diagnosed worldwide in 2024 — a staggering 2.3 million in total — were caused by infectious agents. The findings, drawn from the IARC’s Global Cancer Observatory database and published in The Lancet Oncology on September 28, 2026, represent the most exhaustive accounting of infection-attributable cancer ever compiled, encompassing not only familiar culprits such as HPV and H. pylori but also newly recognized carcinogenic agents including HIV and Merkel cell polyomavirus. While the scale of the problem is formidable, medical experts emphasize that a meaningful portion of these cancers could have been avoided through existing tools — vaccines, screenings, and targeted treatments — that are already within reach.

A Landmark IARC Analysis Quantifies the Infectious Cancer Burden

The study, conducted in France under the auspices of the IARC — a specialized branch of the World Health Organization — analyzed cancer burden data for the year 2024 and identified twelve specific infectious agents with confirmed links to human cancers. That list includes Helicobacter pylori, human papillomavirus (HPV), hepatitis B virus (HBV), hepatitis C virus (HCV), Epstein–Barr virus (EBV), Kaposi sarcoma-associated herpesvirus, Schistosoma haematobium, HTLV-1, Opisthorchis viverrini, Clonorchis sinensis, Merkel cell polyomavirus, and HIV. The research is notable for its expanded scope compared with prior iterations of this analysis, incorporating newer infection-cancer links such as the relationship between Epstein–Barr virus and gastric cancer.

The study’s release places renewed urgency on existing public health infrastructure. Researchers determined that the total toll of 2.3 million infection-attributable cancers in 2024 represents approximately 12 percent of all new cancer diagnoses that year — a proportion equivalent, in scale, to the entire burden of lung cancer across all cancer types in the United States. Dr. Rumgay further noted that despite meaningful advances in vaccination and cancer screening programs in recent years, the challenge of infection-driven cancer remains acute, with the heaviest burden concentrated in low- and middle-income nations.

Five Pathogens Drive the Vast Majority of Infection-Linked Cancer Cases

While twelve infectious agents were identified in total, five were responsible for the overwhelming share of the global figure. Helicobacter pylori led with an estimated 760,000 associated cancer cases, followed closely by HPV at approximately 750,000 cases. Hepatitis B virus accounted for around 360,000 cases, while Epstein–Barr virus was linked to some 260,000. Hepatitis C virus contributed roughly 160,000 additional cases. Together, these five infections account for nearly the entirety of the 2.3 million global total.

Understanding HPV, H. Pylori, and Their Cancer Links

For Dr. Joshua Cohen, medical director of the Gynecologic Cancer Program at City of Hope Orange County in Irvine, California, the HPV statistics carry particular weight in the clinical setting. HPV stands as one of the most frequently encountered drivers of cancers involving the rectum, vagina, cervix, and the oropharynx — the region at the back of the throat — and approximately 40,000 people in the United States are diagnosed with HPV-related cancers every year. An estimated 80 percent of the population encounters at least one HPV strain over the course of a lifetime, yet in most cases the body’s immune response successfully clears the virus without any intervention. What determines why some immune systems fail to do so remains an open question in medicine.

H. pylori occupies a different niche in the infection-cancer landscape. As a stomach-dwelling bacterium, it has been firmly established as a driver of gastric cancer — a disease that, while less common in the United States than in regions such as Southeast Asia, remains a serious global health concern. In the United States, universal H. pylori screening is not standard practice, but Cohen advises that individuals experiencing peptic ulcer disease or significant epigastric pain should consult a gastroenterologist to discuss testing and, if necessary, treatment for the infection.

What the Data Cannot Fully Capture — Study Limitations

The researchers were candid about the constraints of their methodology. Because the study relied on population-level data aggregated from national cancer registries rather than tracking individual patient trajectories over time, the accuracy of its conclusions depends heavily on the completeness and quality of cancer surveillance data available in each country. In many low- and middle-income nations, registry coverage is limited, requiring statisticians to model national figures from regional sampling — a process that introduces uncertainty. Furthermore, the analysis was confined to infections that have already been formally designated as human carcinogens; agents whose cancer-causing potential is suspected but not yet conclusively established were excluded, meaning the true total burden of infection-attributable cancer may be higher than the 2.3 million figure suggests.

Vaccination, Screening, and Early Treatment as Cancer Prevention Tools

Despite the sobering scale of the findings, Dr. Cohen was measured in framing what they mean for individual patients. The existence of a statistical association between a given infection and cancer does not translate to an inevitable personal outcome — the vast majority of people living with HPV, H. pylori, hepatitis B, or hepatitis C will not develop cancer. That said, the presence of these infections does elevate risk, and the appropriate medical response is to seek treatment rather than to assume no action is necessary. Cohen emphasized that the United States is relatively well-positioned compared to other parts of the world, partly because Americans have access to the HPV vaccine — a tool he described as providing meaningful protective coverage against oropharyngeal, cervical, vaginal, penile, and anal cancers.

Cohen also encouraged patients to think proactively about their health and the health of their families. His core message centers on a two-part framework: first, taking steps to prevent acquiring these infections in the first place; and second, for those who already have one of the listed infections, asking what can be done to reduce the downstream risk of developing cancer. Symptoms that warrant prompt medical evaluation include epigastric pain — a discomfort localized to the upper middle region of the abdomen — persistent acid reflux, abnormal vaginal bleeding, or difficulty and pain with swallowing. These presentations can signal underlying conditions that may intersect with both infection and cancer risk. Doctors, Cohen noted, have a meaningful toolkit available to help keep patients safe once an infection is identified.

What the Global Infection-Cancer Link Means for Patients and Public Health

The IARC’s 2024 analysis is, at its core, a data-driven argument for prevention. By pinpointing the infectious origins of more than two million cancer cases in a single year, researchers have handed policymakers and clinicians a quantifiable and actionable target — one that existing vaccines, antimicrobial therapies, and screening protocols are already equipped to address, at least in part. The findings also serve as a reminder that cancer, despite its complexity, does not always begin in isolation; for a meaningful fraction of patients, the story starts with a pathogen. That recognition, paired with the clinical guidance of specialists like Dr. Cohen, reinforces a straightforward but powerful message: understanding and managing infection risk is not separate from cancer prevention — it is a central part of it.